DRUG INFORMATION Sample Clauses

DRUG INFORMATION. In order to achieve rotation goals and objectives, the resident will complete the following activities: • Respond both verbally and in writing to drug information requests that support patient care and research activities. o Document each of these “informal” drug information requests and their associated response using the departmental intervention software, Theradoc. o Provide written responses to a minimum of 2 researched drug information question of at least moderate complexity by the end of the residency year (at least 1 completed by the second quarter). The expectation is that this will be of quality for submission for publication. o Written responses may be directed to questions encountered and researched during clinical rotations and/or weekend staffing assignments. • Prepare and present at least one (1) unbiased formulary monograph or class review to guide the Pharmacy and Therapeutics Committee (and associated sub-committees) in their formulary decisions. • Co-ordinate and present to the Pharmacy and Therapeutics Committee (and associated sub- committees) at least one (1) medication use evaluation. • Design and implement an intervention to change a problematic or potentially problematic aspect of the medication-use system with the objective of improving quality. • Develop or modify at least one (1) medication use policies. These policies may pertain to the resident’s project, MUE, formulary monograph, or quality improvement project if applicable. • Educate staff on pertinent drug topics. o Provide in-service education as requested. • Actively participate in the institution’s Adverse Drug Event Reporting Program. o Document all identified ADRs in Patient Safety Network (PSN) o Document all identified near misses and medication events using the online ADE reporting program (PSN).
AutoNDA by SimpleDocs
DRUG INFORMATION. In order to achieve rotation goals and objectives, the resident will complete the following activities: • Prepare and present at least one (1) unbiased formulary monograph or class review to guide the Pharmacy and Therapeutics Committee (and associated sub-committees) in their formulary decisions. • Co-ordinate and present to the Pharmacy and Therapeutics Committee (and associated sub- committees) at least one (1) medication use evaluation. • Present and critique at least three (3) recently published medical/pharmaceutical articles. To be determined by the Drug Information preceptor. • Design and implement an intervention to change a problematic or potentially problematic aspect of the medication-use system with the objective of improving quality. • Develop or modify at least one (1) medication use policies. These policies may pertain to the resident’s project, MUE, formulary monograph, or quality improvement project if applicable. • Educate staff on pertinent drug topics. o Provide in-service education as requested. o Prepare one (1) Bugs and Drugs and Prescription for Safety newsletter article for publication. • Actively participate in the institution’s Adverse Drug Event Reporting Program. o Document all identified ADRs in Patient Safety Network (PSN) o Document all identified near misses and medication events using the online ADE reporting program (PSN).
DRUG INFORMATION. In order to achieve rotation goals and objectives, the resident will complete the following activities: • Respond both verbally and in writing to drug information requests that support patient care and research activities. o Document each of these “informal” drug information requests and their associated response using the departmental intervention software, Theradoc. o Provide a formal written response to one (1) thoroughly researched drug information question of at least moderate complexity. There is a 2500 maximum word limit. Drug info question response must be completed by the end of the second quarter. A second drug information question response may be assigned at the discretion of the drug information preceptor depending on the quality of the first formal response. o Written responses may be directed to questions encountered and researched during clinical rotations and/or weekend staffing assignments. • Prepare and present at least one (1) unbiased formulary monograph or class review to guide the Pharmacy and Therapeutics Committee (and associated sub-committees) in their formulary decisions. • Co-ordinate and present to the Pharmacy and Therapeutics Committee (and associated sub- committees) at least one (1) medication use evaluation. • Present and critique at least four (4) recently published medical/pharmaceutical articles (3 quarterly journal clubs and 1 student case conference discussions). To be determined by the Drug Information preceptor. • Design and implement an intervention to change a problematic or potentially problematic aspect of the medication-use system with the objective of improving quality. • Develop or modify at least two (2) medication use policies. These policies may pertain to the resident’s project, MUE, formulary monograph, or quality improvement project if applicable. • Educate staff on pertinent drug topics. o Provide in-service education as requested. o Prepare one (1) Bugs and Drugs and Prescription for Safety newsletter article for publication. • Actively participate in the institution’s Adverse Drug Event Reporting Program. o Document all identified ADRs in Patient Safety Network (PSN) o Document all identified near misses and medication events using the online ADE reporting program (PSN).

Related to DRUG INFORMATION

  • Information The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Securities which have been requested by the Buyer or its advisors. The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, afforded the opportunity to ask questions of the Company. Notwithstanding the foregoing, the Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to or promptly following such disclosure to the Buyer. Neither such inquiries nor any other due diligence investigation conducted by Buyer or any of its advisors or representatives shall modify, amend or affect Buyer’s right to rely on the Company’s representations and warranties contained in Section 3 below. The Buyer understands that its investment in the Securities involves a significant degree of risk. The Buyer is not aware of any facts that may constitute a breach of any of the Company's representations and warranties made herein.

Time is Money Join Law Insider Premium to draft better contracts faster.